Sanofi Inks Letter Of Intent With pan-Canadian Pharmaceutical Alliance For Dupixent For Four Additional Indications

Sanofi has signed a Letter of Intent with the pan-Canadian Pharmaceutical Alliance for its drug Dupixent, expanding its indications to include atopic dermatitis in pediatric patients, prurigo nodularis, severe chronic rhinosinusitis with nasal polyposis, and chronic obstructive pulmonary disease. The company aims to collaborate with public payers to enhance access for eligible patients.